BioPharmSignal logoBioPharmSignal

Biotech News

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma

Allogene Therapeutics (ALLO)Allogene TherapeuticsFDA / regulatory

FDA Granted RMAT Designation Based on ALPHA3 Trial Futility Analysis, Highlighting Cema-Cel’s Potential to Transform Disease Treatment in First-Line LBCL Consolidation Cema-Cel Induced Rapid and Substantial MRD Clearance of 58.3%, with a 97.7% Median Decrease in Plasma ctDNA at Day 45, Compared

Related news

ALLOAllogene Therapeutics2026-04-13 11:30 EST

Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

ALLOAllogene Therapeutics2026-04-10 20:02 EST

Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026

MBIOMustang Bio2025-07-07 12:30 EST

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma

MBIOMustang Bio2024-11-07 13:30 EST

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

LEGNLegend Biotech Corporation2026-06-15 12:00 EST

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

LEGNLegend Biotech Corporation2025-12-06 19:00 EST

Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025

View all latest news

Allogene Therapeutics

Allogeneic CAR T Company Allogene Therapeutics develops off-the-shelf CAR T-cell therapies for cancer and autoimmune disease. Cema-cel Cemacabtagene ansegedleucel, or cema-cel, is a CD19-directed AlloCAR T candidate designed for rapid administration without patient-specific manufacturing. First-Line LBCL Strategy The pivotal Phase 2...

Recent company news

ALLOAllogene Therapeutics2026-08-04 12:30 EST

Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update

ALLOAllogene Therapeutics2026-07-29 12:30 EST

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma

ALLOAllogene Therapeutics2026-07-15 12:30 EST

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors

ALLOAllogene Therapeutics2026-05-28 21:02 EST

Allogene Therapeutics Announces Planned CEO Succession

ALLOAllogene Therapeutics2026-05-26 12:30 EST

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Stock data

Close
1.97 USD
Market cap
707.57M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States